The aim of this report is to assess the added benefit of crizotinib in patients with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC)
http://ift.tt/2seTuZW
http://ift.tt/2rzqRoy
Πέμπτη 15 Ιουνίου 2017
Crizotinib -- Benefit Assessment According to §35a Social Code Book V [Internet].
http://ift.tt/2rzqRoy
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Endoscope-assisted extreme-lateral interbody fusion (XLIF) - preliminary experience and technical note. World Neurosurg. 2017 Apr 26;:...
-
The aim of the present report is to assess the added benefit of the drug dasabuvir in comparison with dual therapy of peginterferon and riba...
-
http://ift.tt/2pg0mo0 http://ift.tt/2pdHIzT
-
Frequency and specific characteristics of the incomplete partition type III anomaly in children : Objectives/Hypothesis To determine the...
-
Abstract Background Paediatric rheumatology service in Sub-Sahara African is virtually not available as there is a shortage of paediatric ...
-
Publication date: Available online 16 June 2017 Source: Journal of Cranio-Maxillofacial Surgery Author(s): Berthold H. Hell There are sev...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου